Briefing
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
ctDNA dynamics from 217 patients at six centers, training and validation. Before therapy, ctDNA was detectable in 98%; pretreatment levels were prognostic in front-line and salvage settings. In the first validation set, front-line patients achieving EMR or MMR had superior 24-month EFS (EMR 83% vs 50%, P=0.0015; MMR 82% vs 46%, P<.001). EMR also predicted salvage 24-month EFS (100% vs 13%, P=0.011). Molecular response was independently prognostic including after adjustment for IPI and interim PET/CT. Level 2.
- Design: paper
- n: 217
- Assay: CAPP-Seq ctDNA; early molecular response (EMR) and major molecular response (MMR)